| Oct 9 |
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
|
| Oct 7 |
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
|
| Sep 25 |
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
|
| Sep 23 |
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
|
| Sep 10 |
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
|
| Sep 3 |
Kronos Bio Announces Participation in Medical and Investor Conferences in September
|
| Aug 22 |
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
|
| Aug 11 |
Kronos Bio Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 9 |
Kronos Bio GAAP EPS of -$0.27, revenue of $2.69M
|
| Aug 8 |
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
|
